Please note: We are currently experiencing some performance issues across the site, and some pages may be slow to load. We are working on restoring normal service soon. Importing new articles from Word documents is also currently unavailable. We apologize for any inconvenience.

loading page

Small-molecule natural products for reversing liver fibrosis based on modulation of HSCs activation: an update
  • +1
  • Yu Zheng,
  • Zejun Yang,
  • Kaipei Luo,
  • Xiaofang Li
Yu Zheng
Chengdu College of Traditional Chinese Medicine

Corresponding Author:[email protected]

Author Profile
Zejun Yang
Chengdu College of Traditional Chinese Medicine
Author Profile
Kaipei Luo
Chengdu College of Traditional Chinese Medicine
Author Profile
Xiaofang Li
Chengdu College of Traditional Chinese Medicine
Author Profile

Abstract

Liver fibrosis (LF) is a trauma repair process carried out by the liver in response to various acute and chronic liver injuries, featured by excessive proliferation as well as abnormal dismissal of extracellular matrix as the main pathological features, and its continuous development will deteriorate into cirrhosis, liver cancer as well as other illnesses. The occurrence of LF is closely related to Hepatic stellate cells (HSCs) stimulation, and intervention in HSCs proliferation is expected to reverse LF. Plant-based small molecule drugs have anti-LF effects, and their mechanisms of action are related to anti-inflammation, anti-oxidative stress, as well as inhibition of abnormal accumulation of extracellular matrix. Consequently, new agents for HSCs will be required to furnish a possible curative response. Small-molecule natural products might be attractive for LF therapy. That is because they not only have the effect against HSCs, but also have excellent qualities such as low toxic side effects and easy availability from the perspective of safety and cost. In this review, we provide an updated review of the signal transduction pathways involved in HSCs and small-molecule natural products targeting HSCs reported in the past 3 years at home and abroad, with the aim of providing new ideas for the development of plant-based small molecule drugs targeting HSCs to reverse LF.